PDCD1 and non-small cell lung carcinoma: Moreover, analysis of transcriptome sequencing data from 16 non-small cell lung cancer patients treated with nivolumab or pembrolizumab (PD-1 antibodies) revealed that, among these patients, five experienced disease remission while eleven did not.